concept

PRMT1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PRMT1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

445Connections

2Hypotheses

1Analyses

50Outgoing

50Incoming

Summary

PRMT1 is a concept in neurodegeneration research. Key relationships include: inhibits, implicated in, regulates. Associated with AD, ALI, ALS. Connected to 112 entities in the SciDEX knowledge graph.

View on Wiki →

💡 Concept Info

Name	PRMT1
Key Genes/Proteins	SREBF1, DDX1, PHGDH, PFKFB3, PKM2
Related Diseases	Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, PHGDH enzymatic activity, chemoresistance
Related Pathways	De Novo Fatty Acid Synthesis
Linked Hypotheses	1 hypotheses

🔮 Predicted Structure: PRMT1 — AlphaFold A0A3S6H7X9 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    PRMT1["PRMT1"]
    PRMT1 -->|"target for"| Cancer["Cancer"]
    PRMT1 -->|"target for"| Cardiovascular["Cardiovascular"]
    PRMT1 -->|"target for"| Ms["Ms"]
    PRMT1 -->|"target for"| Tumor["Tumor"]
    PRMT1 -->|"target for"| Als["Als"]
    PRMT1 -->|"regulates"| Aging["Aging"]
    h_19003961["h-19003961"] -->|"targets"| PRMT1
    FASN["FASN"] -->|"activates"| PRMT1
    KRAS["KRAS"] -->|"inhibits"| PRMT1
    PHGDH["PHGDH"] -->|"activates"| PRMT1
    IDH1["IDH1"] -->|"regulates"| PRMT1
    P38["P38"] -->|"regulates"| PRMT1
    CANCER["CANCER"] -->|"inhibits"| PRMT1
    PRMT5["PRMT5"] -->|"inhibits"| PRMT1
    DNA["DNA"] -->|"regulates"| PRMT1

Outgoing (315)

Target	Relation	Type	Str
De Novo Fatty Acid Synthesis	associated_with	pathway	0.95
Pancreatic Ductal Adenocarcinoma	associated_with	disease	0.95
PANCREATIC CANCER	associated_with	entity	0.95
SREBF1	interacts_with	gene	0.95
DDX1	mediates	protein	0.95
PHGDH	phosphorylates	protein	0.95
PHGDH	associated_with	gene	0.95
PFKFB3	associated_with	protein	0.95
PKM2	associated_with	protein	0.95
Pancreatic Cancer	promotes	disease	0.95
PHGDH enzymatic activity	activates	phenotype	0.94
chemoresistance	drives	phenotype	0.93
Cancer Cell Proliferation	activates	process	0.90
Tumorigenesis	associated_with	process	0.90
Pancreatic Cancer Development	mediates	process	0.90
CHEMORESISTANCE	contributes_to	entity	0.90
Fatty Acid Synthesis	associated_with	pathway	0.90
Triple-Negative Breast Cancer	associated_with	disease	0.90
Cancer Development	associated_with	process	0.90
Tumorigenesis	mediates	process	0.90
Anti-Cancer Drug Resistance	involved_in	phenotype	0.90
Cancer Cell Proliferation	regulates	process	0.90
Tumorigenesis	involved_in	process	0.90
Chemotherapy Resistance	promotes	phenotype	0.90
anti-cancer drug resistance	drives	phenotype	0.90
SREBF1	phosphorylates	gene	0.90
PARP inhibitor	therapeutic_target	drug	0.90
DDX1	phosphorylates	protein	0.90
Cholangiocarcinoma	contributes_to	disease	0.90
Cholangiocarcinoma	therapeutic_target	disease	0.90
p38 mitogen-activated protein kinase	regulates	protein	0.90
skeletal muscle atrophy	protects_against	disease	0.90
Tacrolimus-Induced Chronic Nephrotoxicity	implicated_in	disease	0.90
Chemoresistance	associated_with	phenotype	0.90
PHGDH	modulates	gene	0.90
Pancreatic Cancer	expressed_in	disease	0.90
Cancer	targets	disease	0.90
CANCER	therapeutic_target	entity	0.90
PFKFB3	phosphorylates	entity	0.90
PKM2	phosphorylates	entity	0.90
CELL PROLIFERATION	regulates	entity	0.90
TUMORIGENESIS	contributes_to	entity	0.90
CHEMOTHERAPY RESISTANCE	associated_with	entity	0.90
Gastric Cancer	associated_with	disease	0.90
Chemoresistance	promotes	phenotype	0.90
lipid metabolism	regulates	process	0.90
Breast Cancer	therapeutic_target	disease	0.90
PKM2	methylates	protein	0.90
Triple-Negative Breast Cancer	therapeutic_target	disease	0.88
Chemotherapy Resistance	contributes_to	phenotype	0.85

Incoming (130)

Source	Relation	Type	Str
Ginger	targets	compound	0.95
Tc-E-5003	inhibits	compound	0.95
Gsk715	targets	drug	0.90
exercise preconditioning	upregulates	process	0.90
PRMT inhibitors	targets	drug	0.90
h-19003961	targets_gene	hypothesis	0.90
h-ccc05373	targets_gene	hypothesis	0.90
EGR1	regulates	entity	0.85
GINGER	inhibits	entity	0.85
EGR1	activates	gene	0.85
Ginsenoside RG3	inhibits	compound	0.85
DDX1	upregulates	protein	0.85
h-19003961	targets	hypothesis	0.80
Cantharidin	inhibits	drug	0.80
USP10	associated_with	protein	0.80
Ginger Active Ingredients	binds	compound	0.70
Ginger Active Ingredients	inhibits	compound	0.70
FUS	accumulates_in	gene	0.70
FUS	associated_with	gene	0.70
ALS	accumulates_in	gene	0.70
FASN	activates	gene	0.60
EGR1	associated_with	gene	0.60
IDH1	regulates	gene	0.60
P38	regulates	gene	0.60
PRMT5	inhibits	gene	0.60
PRMT5	regulates	gene	0.60
PINK1	activates	gene	0.60
FASN	inhibits	entity	0.60
TDP-43	regulates	gene	0.60
PRMT5	therapeutic_target	gene	0.60
OVERVIEW	expressed_in	gene	0.60
glycolysis	activates	pathway	0.60
FUS	modulates	gene	0.60
FUS	implicated_in	gene	0.60
FUS	activates	gene	0.60
FUS	protects_against	gene	0.60
AKT	inhibits	gene	0.60
PI3K	inhibits	gene	0.60
AKT	regulates	gene	0.60
PI3K	regulates	gene	0.60
FUS	interacts_with	gene	0.60
BMP2	expressed_in	gene	0.60
DDX1	associated_with	gene	0.60
DDX1	regulates	gene	0.60
DDX1	activates	gene	0.60
DDX1	targets	gene	0.60
PFKM	activates	gene	0.60
KRAS	inhibits	gene	0.60
PHGDH	activates	gene	0.60
CANCER	inhibits	gene	0.60

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph	0.615	neurodegeneration	What is the therapeutic window between i
Arginine Methylation Enhancement Therapy	0.463	neurodegeneration	TDP-43 phase separation therapeutics for

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.575

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibi [PMID:40446574]	Chen G, Gou B, Du Y, Zhou Z, Bai Y, Yang	Phytomedicine	2025	1
PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. [PMID:38460517]	Ku B, Eisenbarth D, Baek S, Jeong TK, Ka	Cell Rep Med	2024	1
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemor [PMID:38383964]	Yamamoto T, Hayashida T, Masugi Y, Oshik	Cancer Res	2024	1
Promising role of protein arginine methyltransferases in overcoming anti-cancer [PMID:37980859]	Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Z	Drug Resist Updat	2024	1
Protein arginine methylation: from enigmatic functions to therapeutic targeting. [PMID:33742187]	Wu Q, Schapira M, Arrowsmith CH, Barsyte	Nat Rev Drug Discov	2021	1
Repression of PRMT activities sensitize human homologous recombination-proficien [PMID:41632514]	["Zhang Y", "Xu M", "Yuan J", "Hu Z", "J	eLife	2026	0
Ginsenoside RG3 and cantharidin synergistically suppress the progression of hepa [PMID:41501793]	["Wang Y", "Yuan H", "Yu Y", "Gou X", "W	Journal of translational medic	2026	0
Protein arginine methyltransferases in cancer: mechanisms, functions, and therap [PMID:41928257]	Jeong Y, Cho Y, Kim YK	J Biomed Sci	2026	0
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, [PMID:41801765]	Thiebaut C, Martinez S, Pruvost L, Eve L	Cancer science	2026	0
Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase [PMID:41903671]	Wu Z, Wang Y, Yu B, Yu R, Chen M, Chen Z	Cancer letters	2026	0
LC-MS profiling of [PMID:41756837]	["Basirattalab A", "Wallis D", "Hartel N	bioRxiv : the preprint server	2026	0
Discovery of the First-in-Class Protein Arginine Methyltransferase 1 PROTAC Degr [PMID:41830641]	Guo S, Li J, Lin J, Chen Y, Liu C, Liu H	Journal of medicinal chemistry	2026	0
PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulatin [PMID:41912914]	Tian Z, Gao P, Zhang Y, Ma J, Hu X, Wang	Leukemia	2026	0
PFKM governs metabolic shifts throughout skeletal muscle differentiation. [PMID:41735679]	["Campos M", "Nguyen S", "Kong X", "Yang	Nature metabolism	2026	0
PRMT1-rich exosomes derived from M2 macrophages as novel therapeutics for enhanc [PMID:41610641]	["Hong H", "Zhou C", "Wang H", "Lin C",	Tissue & cell	2026	0
Exercise preconditioning prevents immobilization-induced skeletal muscle atrophy [PMID:41737591]	["Yang X", "Zou Y", "Wang H", "Niu Y", "	Sports medicine and health sci	2026	0
Arginine methylation-dependent stabilization of SUV39H1 promotes breast cancer g [PMID:41795022]	Zhao W, Wang G, Wang P, Ma B, Liu B, Fu	Oncogene	2026	0
PRMT1-mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes [PMID:41668296]	["Liu W", "Liao Y", "Kuai Y", "Gao X", "	Clinical and molecular hepatol	2026	0
Trans-Omic Analysis Identifies the 'PRMT1-STAT3-Integrin αVβ6 Axis' as a Novel T [PMID:41226322]	["Nishida S", "Ishima T", "Iwami D", "Na	International journal of molec	2025	0
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine meth [PMID:39817908]	Aikio M, Odeh HM, Wobst HJ, Lee BL, Chan	Cell Rep	2025	0

PRMT1

Understanding Entity Pages

Summary

Wiki Pages (20)

nimodipine-als

FOXO1 Protein

amiloride-als

Riluzole ALS Trials

Lithium Continuation in ALS Trial

viral-post-infectious-als

TDP-43 Protein

High-Dose Vitamins ALS Trial

Tauraso (Nimodipine) ALS Trial

Update TDP-43 protein page with comprehensive content

Neuroimmune Dysfunction in Frontotemporal Dementia

Lithium Carbonate in Amyotrophic Lateral Sclerosis

Epigenetics in Amyotrophic Lateral Sclerosis

PGC-1α (PPARGC1A)

Anti-Tau Therapeutics

Spinal Cord Motor Neurons in Amyotrophic Lateral Sclerosis

ER Stress & UPR Therapeutics Investment Landscape

Masitinib ALS Trial

Epigenetic Regulation